The molecule

ACE-031 identity

Identifiers, parent molecule, targets and development stage, from curated data.

Ramatercept fuses a soluble human activin receptor IIB domain to a human IgG1 Fc fragment through a glycine linker. GSRS records two identical 343-residue chains, interchain disulfides and N-glycosylation sites. It traps receptor ligands rather than acting as a small peptide. The defined fusion supports kind conjugate rather than undefined_product. ACE-011, ACE-536 and bimagrumab are distinct agents. The trial program stopped after vascular safety concerns.

Kind: Conjugate · 343 residues
Identifiers: ChEMBLCHEMBL2108674 (opens in a new tab)UNII42HQC6QLEK (opens in a new tab)DrugBankDB15116 (opens in a new tab)CAS1169766-01-1
Development: Phase 2Acceleron Pharma and ShireNCT01099761 is phase 2 and terminated. The registry gives the reason: Based on preliminary safety data. The current registry sponsor is Acceleron Pharma, a Merck subsidiary. Acceleron and Shire stopped further ACE-031 development in April 2013. Their collaboration ended on June 30, 2013, according to the Acceleron filing. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Myostatin and other activin receptor IIB ligands	Soluble receptor ligand trap	curated database or regulator descriptionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

343 amino acids · 3 modifications · 7 disulfide bonds

H-

GRGEAETREC

IYYNANWELE

RTNQSGLERC

EGEQDKRLHC

YASWRNSSGT

IELVKKGCWL

DDFNCYDRQE

CVATEENPQV

YFCCCEGNFC

NERFTHLPEA

GGPEVTYEPP

PTAPTGGGTH

TCPPCPAPEL

LGGPSVFLFP

PKPKDTLMIS

RTPEVTCVVV

DVSHEDPEVK

FNWYVDGVEV

HNAKTKPREE

QYNSTYRVVS

VLTVLHQDWL

NGKEYKCKVS

NKALPVPIEK

TISKAKGQPR

EPQVYTLPPS

REEMTKNQVS

LTCLVKGFYP

SDIAVEWESN

GQPENNYKTT

PPVLDSDGSF

FLYSKLTVDK

SRWQQGNVFS

CSVMHEALHN

HYTQKSLSLS

PGK

-OH

Properties

From identity sources

No formula or molecular weight is listed for ACE-031 (ramatercept).

Calculated from the sequence

pKa set

Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): −0.692; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 60,850 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Extinction coefficient, 280 nm (all Cys as cystines): 61,850 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 47.46; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 60.1; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.98 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.485; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984

Not included: other modification. Mass, charge and pI are not calculated; use the identity-source values.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Composition

Hydrophobic21% (72)A I L M V
Aromatic10% (33)F W Y
Positive13% (45)H K R
Negative13% (46)D E
Polar23% (80)N Q S T
Special20% (67)C G P

343 residues. Each residue counts in one class; F and W count as aromatic.

A Ala12 · 3%

I Ile6 · 2%

L Leu23 · 7%

M Met3 · 1%

V Val28 · 8%

F Phe11 · 3%

W Trp7 · 2%

Y Tyr15 · 4%

H His9 · 3%

K Lys22 · 6%

R Arg14 · 4%

D Asp13 · 4%

E Glu33 · 10%

N Asn19 · 6%

Q Gln13 · 4%

S Ser24 · 7%

T Thr24 · 7%

C Cys16 · 5%

G Gly22 · 6%

P Pro29 · 8%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.056
μH, best 11-residue window: 0.485
Arrow direction: 302°
Residues: 1–54 of 343 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	G	0°	0.48
2	R	100°	-2.53
3	G	200°	0.48
4	E	300°	-0.74
5	A	40°	0.62
6	E	140°	-0.74
7	T	240°	-0.05
8	R	340°	-2.53
9	E	80°	-0.74
10	C	180°	0.29
11	I	280°	1.38
12	Y	20°	0.26
13	Y	120°	0.26
14	N	220°	-0.78
15	A	320°	0.62
16	N	60°	-0.78
17	W	160°	0.81
18	E	260°	-0.74
19	L	0°	1.06
20	E	100°	-0.74
21	R	200°	-2.53
22	T	300°	-0.05
23	N	40°	-0.78
24	Q	140°	-0.85
25	S	240°	-0.18
26	G	340°	0.48
27	L	80°	1.06
28	E	180°	-0.74
29	R	280°	-2.53
30	C	20°	0.29
31	E	120°	-0.74
32	G	220°	0.48
33	E	320°	-0.74
34	Q	60°	-0.85
35	D	160°	-0.90
36	K	260°	-1.50
37	R	0°	-2.53
38	L	100°	1.06
39	H	200°	-0.40
40	C	300°	0.29
41	Y	40°	0.26
42	A	140°	0.62
43	S	240°	-0.18
44	W	340°	0.81
45	R	80°	-2.53
46	N	180°	-0.78
47	S	280°	-0.18
48	S	20°	-0.18
49	G	120°	0.48
50	T	220°	-0.05
51	I	320°	1.38
52	E	60°	-0.74
53	L	160°	1.06
54	V	260°	1.08

Results by area

ACE-031 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

6 of 12 studies have results (50%), published 2010 to 2026. Top row: every study. Bottom row: studies with results about ACE-031 (ramatercept), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies12 in all, 2010 to 2026

Studies with results6 in all, 2010 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

ACE-031 studies on side effects

5 results · people 5 · animals 0 · lab 0

5 results

In boys with Duchenne muscular dystrophy, possible widened small blood vessels contributed to stopping the ACE‑031 trial.Muscle & nerve, 2017
In boys with Duchenne muscular dystrophy, ACE‑031 was not associated with serious or severe adverse events.Muscle & nerve, 2017
In boys with Duchenne muscular dystrophy, possible nosebleed concerns contributed to stopping the ACE‑031 trial.Muscle & nerve, 2017
In healthy postmenopausal women, adverse events with ACE‑031 included redness at the injection site.Muscle & nerve, 2013
In healthy postmenopausal women, a single ACE‑031 dose was generally well tolerated.Muscle & nerve, 2013

ACE-031 studies on muscles and tendons

21 results · people 3 · animals 18 · lab 0

Top 3 of 21 results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased lean body mass.Muscle & nerve, 2017
In healthy postmenopausal women, ACE‑031 increased lean body mass at day 29.Muscle & nerve, 2013
In healthy postmenopausal women, ACE‑031 increased thigh muscle volume at day 29.Muscle & nerve, 2013

ACE-031 studies on blood levels and clearance

3 results · people 3 · animals 0 · lab 0

3 results

In healthy postmenopausal women, total ACE‑031 exposure increased linearly with dose.Muscle & nerve, 2013
In healthy postmenopausal women, peak ACE‑031 levels increased linearly with dose.Muscle & nerve, 2013
In healthy postmenopausal women, the mean ACE‑031 half-life was 10-15 days.Muscle & nerve, 2013

ACE-031 studies on bones and joints

2 results · people 2 · animals 0 · lab 0

2 results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased bone density.Muscle & nerve, 2017
In healthy postmenopausal women, blood marker changes suggested that ACE‑031 also improved bone and fat metabolism.Muscle & nerve, 2013

ACE-031 studies on weight and appetite

2 results · people 1 · animals 1 · lab 0

2 results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward reduced body fat.Muscle & nerve, 2017
In mice, ACE‑031 increased body weight compared with vehicle control.Journal of applied physiology, 2010

ACE-031 studies on daily life and fitness

1 result · people 1 · animals 0 · lab 0

1 result

In boys with Duchenne muscular dystrophy, ACE‑031 tended to preserve walking distance versus placebo, but the difference was not significant.Muscle & nerve, 2017

Trials and papers

ACE-031 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

4 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (4 of 4)

4 trials · 2 completed · 2 stopped early · 1 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20082009201020112012

Ph 1
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
NCT00755638
Sept 2008 to Jul 2009
Ph 1
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
NCT00952887
Aug 2009 to Feb 2011
Ph 2
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
NCT01099761
Apr 2010 to Jun 2011
Terminated
Terminated
Ph 2
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
NCT01239758
Oct 2010 to May 2011
Terminated
Terminated

4 trials · 2 completed · 2 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2Results postedNCT01099761

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAn = 24Apr 2010 to Jun 2011

Duchenne Muscular Dystrophy

Trial page ClinicalTrials.govUpdated 13 Oct 2022

TerminatedPhase 2NCT01239758

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAn = 11Oct 2010 to May 2011

Duchenne Muscular Dystrophy

Trial page ClinicalTrials.govUpdated 1 Feb 2013

CompletedPhase 1NCT00952887

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAn = 70Aug 2009 to Feb 2011

Muscular Atrophy

Trial page ClinicalTrials.govUpdated 23 Mar 2011

CompletedPhase 1NCT00755638

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAn = 48Sept 2008 to Jul 2009

Muscle Loss

Trial page ClinicalTrials.govUpdated 14 Jul 2009

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

12 studies match. Retracted studies are left out.

Showing 11 of 12 studiesquery qry_3b49a01a91fb935a6f5c2897

Studies with results

6 studies

Randomized controlled trial · 2017

7 results

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Campbell et al. 2017Muscle & nervecited by 190

PMID 27462804DOI 10.1002/mus.25268PUB-27462804

Full text at the publisher7 results where ACE-031 (ramatercept) was given

Publisher page See results (7)

Randomized controlled trial · 2013

8 results

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Attie et al. 2013Muscle & nerven = 48cited by 146

PMID 23169607DOI 10.1002/mus.23539PUB-23169607

Full text at the publisher8 results where ACE-031 (ramatercept) was given

Publisher page See results (8)

Animal study (in vivo) · mouse · 2010

14 results

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Cadena et al. 2010Journal of applied physiology (Bethesda, Md. : 1985)cited by 106

PMID 20466801PMC2944638DOI 10.1152/japplphysiol.00866.2009PUB-20466801

Rights unknown14 results where ACE-031 (ramatercept) was given

Source link See results (14)

Not a test of ACE-031 (ramatercept) alone · 2022

1 result

The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.

Li et al. 2022PloS onecited by 19

PMID 36054096PMC9439232DOI 10.1371/journal.pone.0273193PUB-36054096

CC BY1 result where ACE-031 (ramatercept) was a tool, carrier or part of a combination

Download PDF See results (1)

Not a test of ACE-031 (ramatercept) alone · 2023

3 results

The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.

Yang et al. 2023Scientific reportscited by 5

PMID 37919345PMC10622500DOI 10.1038/s41598-023-45820-xPUB-37919345

CC BY3 results where ACE-031 (ramatercept) was a tool, carrier or part of a combination

Download PDF See results (3)

Animal study (in vivo) · callithrix jacchus · 2026

5 results

ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).

Cadena et al. 2026PloS onecited by 1

PMID 41686840PMC12904423DOI 10.1371/journal.pone.0342666PUB-41686840

CC BY5 results where ACE-031 (ramatercept) was given

Download PDF See results (5)

More studies

5 studies

PubMed tag: none · 2025

Gel Electrophoretic Detection of Black Market ACE-031.

Reichel et al. 2025Drug testing and analysiscited by 2

PMID 40312924PMC12489275DOI 10.1002/dta.3898PUB-40312924

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: Bibliography · 2010

Gateways to clinical trials.

Tomillero et al. 2010Methods and findings in experimental and clinical pharmacologycited by 1

PMID 20383346PUB-20383346

Full text at the publisher

Publisher page

PubMed tag: none · 2011

[Myostatin blockade therapy for muscular atrophy].

Sunada et al. 2011Brain and nerve = Shinkei kenkyu no shinpo

PMID 22068480PUB-22068480

Full text at the publisher

Publisher page

PubMed tag: none · 2011

[Anti-myostatin antibody therapy for myopathies].

Sunada et al. 2011Rinsho shinkeigaku = Clinical neurology

PMID 22277518DOI 10.5692/clinicalneurol.51.1157PUB-22277518

Full text at the publisher

Publisher page

PubMed tag: Preprint · 2025

ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus)

Cadena et al. 2025bioRxiv

DOI 10.1101/2025.10.01.679778PUB-97878285

Full text at the publisher

Publisher page

No result for ACE-031 (ramatercept) (1 study on this page)

These studies name ACE-031 (ramatercept) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: none · 2016

Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.

Thevis et al. 2016Rapid communications in mass spectrometry : RCMcited by 33

PMID 26842585DOI 10.1002/rcm.7470PUB-26842585

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

ACE-031 (ramatercept) studies: 6 papers with results

Page 1 of 1

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C · Muscle & nerve · 2017
Randomized controlled trial · 7 results
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.
Attie KM · Muscle & nerve · 2013
Randomized controlled trial · 8 results
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.
Cadena SM · Journal of applied physiology (Bethesda, Md. : 1985) · 2010
Animal study (in vivo) · mouse · 14 results
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).
Cadena SM · PloS one · 2026
Animal study (in vivo) · callithrix jacchus · 5 results
The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.
Yang H · Scientific reports · 2023
Not a test of ACE-031 (ramatercept) alone · 3 results
The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.
Li C · PloS one · 2022
Not a test of ACE-031 (ramatercept) alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The openFDA active ingredient search returned no matches. This confirms no matching entry in this database, not worldwide absence of approval.	21 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	No authorised exact product match was found in the EMA central medicine catalogue. National authorisations are outside this check.	21 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S4.3) ACE-031 is explicitly named as a decoy activin receptor.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

5 safety results for ACE-031 (ramatercept).

Human evidence· 5

In healthy postmenopausal women, single-dose ACE‑031 was generally well tolerated.
Randomized controlled trialn = 48
In boys with Duchenne muscular dystrophy, ACE‑031 was not associated with serious or severe adverse events.
Randomized controlled trialn not reported
In boys with Duchenne muscular dystrophy, potential epistaxis concerns contributed to stopping the ACE‑031 trial after the second dosing regimen.
Randomized controlled trialn not reported
In boys with Duchenne muscular dystrophy, potential telangiectasia concerns contributed to stopping the ACE‑031 trial.
Randomized controlled trialn not reported
In healthy postmenopausal women receiving ACE‑031, adverse events included injection site erythema.
Randomized controlled trialn not reported

Doses studied · 2

The doses that these studies used. They are not recommendations.

0.02-3 mg/kgHuman
Species
human
Route
subcutaneous
Duration
Not reported
Design
Randomized controlled trial · n = 48
3 mg/kgHuman
Species
human
Route
subcutaneous
Duration
Not reported
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design	Source
0.02-3 mg/kg	Human	human	subcutaneous	Not reported	Randomized controlled trial · n = 48
3 mg/kg	Human	human	subcutaneous	Not reported	Randomized controlled trial

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000079
Peptide version: 4
Peptide hash: 41f1f88d3fc2779b…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256630
22 Oct 2026UpdatedData version 254482
21 Oct 2026UpdatedData version 226596
21 Oct 2026CreatedData version 213588

For developers

curl -s https://pepbank.io/v1/briefs/ace-031

Evidence summary for ACE-031 (ramatercept): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 5 results from 2 studies: 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Muscle injury and repairMusculoskeletal	Human: 3 results from 2 studies: 2 increase, 1 not reported. Strongest design: Randomized controlled trial	Animal: 18 results from 2 studies: 12 increase, 2 decrease, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	21
PharmacokineticsPharmacology	Human: 3 results from 1 study: 2 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	3
Bone and jointWhole body	Human: 2 results from 2 studies: 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	2
Body weightMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	2
Exercise and physical functionMusculoskeletal	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 5 results from 2 studies: 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Muscle injury and repairMusculoskeletal	Human: 3 results from 2 studies: 2 increase, 1 not reported. Strongest design: Randomized controlled trial	Animal: 18 results from 2 studies: 12 increase, 2 decrease, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	21
PharmacokineticsPharmacology	Human: 3 results from 1 study: 2 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	3
Bone and jointWhole body	Human: 2 results from 2 studies: 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	2
Body weightMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	2
Exercise and physical functionMusculoskeletal	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1

ACE-031 (ramatercept) studies and research data

ACE-031 identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

Helical wheel

ACE-031 results by year and outcome

What the studies measured

ACE-031 studies on side effects

ACE-031 studies on muscles and tendons

ACE-031 studies on blood levels and clearance

ACE-031 studies on bones and joints

ACE-031 studies on weight and appetite

ACE-031 studies on daily life and fitness

ACE-031 trials

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Papers

Studies with results

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.

The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.

ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).

More studies

Gel Electrophoretic Detection of Black Market ACE-031.

Gateways to clinical trials.

[Myostatin blockade therapy for muscular atrophy].

[Anti-myostatin antibody therapy for myopathies].

ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus)

Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.

Newer studies

ACE-031 (ramatercept) studies: 6 papers with results

Regulatory and safety

Human evidence· 5

Doses studied · 2

Data and API

Peptide

Latest changes

For developers

Related peptides

ACE-031 results by year and outcome

ACE-031 studies on side effects

ACE-031 studies on muscles and tendons

ACE-031 studies on blood levels and clearance

ACE-031 studies on bones and joints

ACE-031 studies on weight and appetite

ACE-031 studies on daily life and fitness

ACE-031 trials

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Papers

Studies with results

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.

The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.

ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).

More studies

Gel Electrophoretic Detection of Black Market ACE-031.

Gateways to clinical trials.

[Myostatin blockade therapy for muscular atrophy].

[Anti-myostatin antibody therapy for myopathies].

ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus)

Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.

ACE-031 (ramatercept) studies: 6 papers with results

Regulatory and safety

Human evidence· 5

Doses studied · 2

Data and API